FDA Approves LOPRESSOR — VALIDUS PHARMACEUTICALS LLC

On August 28, 2025, Validus Pharmaceuticals received FDA approval for Lopressor (metoprolol tartrate), which the company characterized as a substantial strategic move to scale oral solid dosage operations and solidify its footprint in the generic cardiovascular market. This NDA win positions Validus to aggressively compete against legacy manufacturers, potentially introducing down-market pressure and driving significant incremental revenue in the occupied beta-blocker space.